Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Intervalo de año de publicación
1.
J Med Chem ; 64(10): 6581-6595, 2021 05 27.
Artículo en Inglés | MEDLINE | ID: mdl-33979164

RESUMEN

Preclinical and clinical development of numerous small molecules is prevented by their poor aqueous solubility, limited absorption, and oral bioavailability. Herein, we disclose a general prodrug approach that converts promising lead compounds into aminoalkoxycarbonyloxymethyl (amino AOCOM) ether-substituted analogues that display significantly improved aqueous solubility and enhanced oral bioavailability, restoring key requirements typical for drug candidate profiles. The prodrug is completely independent of biotransformations and animal-independent because it becomes an active compound via a pH-triggered intramolecular cyclization-elimination reaction. As a proof-of-concept, the utility of this novel amino AOCOM ether prodrug approach was demonstrated on an antimalarial compound series representing a variety of antimalarial 4(1H)-quinolones, which entered and failed preclinical development over the last decade. With the amino AOCOM ether prodrug moiety, the 3-aryl-4(1H)-quinolone preclinical candidate was shown to provide single-dose cures in a rodent malaria model at an oral dose of 3 mg/kg, without the use of an advanced formulation technique.


Asunto(s)
Antimaláricos/química , Éteres/química , Profármacos/química , Quinolonas/química , Administración Oral , Animales , Antimaláricos/farmacocinética , Antimaláricos/farmacología , Antimaláricos/uso terapéutico , Ciclización , Modelos Animales de Enfermedad , Femenino , Semivida , Concentración de Iones de Hidrógeno , Malaria/tratamiento farmacológico , Malaria/parasitología , Ratones , Ratones Endogámicos BALB C , Plasmodium falciparum/efectos de los fármacos , Profármacos/farmacocinética , Profármacos/farmacología , Profármacos/uso terapéutico , Quinolonas/farmacocinética , Quinolonas/farmacología , Quinolonas/uso terapéutico , Solubilidad , Relación Estructura-Actividad
2.
Free Radic Biol Med ; 95: 43-54, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-26952808

RESUMEN

Plasmodium parasites are exposed to endogenous and exogenous oxidative stress during their complex life cycle. To minimize oxidative damage, the parasites use glutathione (GSH) and thioredoxin (Trx) as primary antioxidants. We previously showed that disruption of the Plasmodium berghei gamma-glutamylcysteine synthetase (pbggcs-ko) or the glutathione reductase (pbgr-ko) genes resulted in a significant reduction of GSH in intraerythrocytic stages, and a defect in growth in the pbggcs-ko parasites. In this report, time course experiments of parasite intraerythrocytic development and morphological studies showed a growth delay during the ring to schizont progression. Morphological analysis shows a significant reduction in size (diameter) of trophozoites and schizonts with increased number of cytoplasmic vacuoles in the pbggcs-ko parasites in comparison to the wild type (WT). Furthermore, the pbggcs-ko mutants exhibited an impaired response to oxidative stress and increased levels of nuclear DNA (nDNA) damage. Reduced GSH levels did not result in mitochondrial DNA (mtDNA) damage or protein carbonylations in neither pbggcs-ko nor pbgr-ko parasites. In addition, the pbggcs-ko mutant parasites showed an increase in mRNA expression of genes involved in oxidative stress detoxification and DNA synthesis, suggesting a potential compensatory mechanism to allow for parasite proliferation. These results reveal that low GSH levels affect parasite development through the impairment of oxidative stress reduction systems and damage to the nDNA. Our studies provide new insights into the role of the GSH antioxidant system in the intraerythrocytic development of Plasmodium parasites, with potential translation into novel pharmacological interventions.


Asunto(s)
Glutamato-Cisteína Ligasa/genética , Glutatión Reductasa/genética , Glutatión/metabolismo , Malaria/parasitología , Plasmodium berghei/genética , Animales , Antioxidantes/metabolismo , Núcleo Celular/genética , Daño del ADN/genética , ADN Mitocondrial/genética , Técnicas de Inactivación de Genes , Glutatión/deficiencia , Estadios del Ciclo de Vida/genética , Malaria/tratamiento farmacológico , Malaria/genética , Estrés Oxidativo/genética , Plasmodium berghei/crecimiento & desarrollo , Plasmodium berghei/patogenicidad , Tiorredoxinas/genética , Tiorredoxinas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA